Remetinostat is under clinical development by Medivir and currently in Phase II for Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Squamous Cell Carcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Remetinostat LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Remetinostat overview

Remetinostat (SHP-141) is under development for the treatment of mycosis fungoides (MF) type early-stage cutaneous T-cell lymphoma, squamous cell carcinoma and basal cell carcinoma. It is administered through topical route. The drug candidate is SHAPE (suberohydroxamic acid phenyl ester) molecule which acts by targeting histone deacetylases (HDAC). It was also under development for the treatment of plaque psoriasis and alopecia areata.

Medivir overview

Medivir is a pharmaceutical company that offers the drug discovery and development of treatments for cancer. The company’s product indications include cutaneous T-cell lymphoma, osteoarthritis, solid tumors, hepatocellular carcinoma and acute myeloid leukemia. Medivir also provides products in partnership with other pharmaceutical companies for the disease areas of hepatitis C and labial herpes. The company operates through a research unit in Huddinge, Sweden. Medvir is headquartered in Huddinge, Sweden.

For a complete picture of Remetinostat’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.